text:
PFE : Analysis & Opinions
Pharma & Biotech Stock Outlook - March 2014 - Industry OutlookMarch 25, 2014Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
These Companies Know The Future Before It HappensFebruary 13, 2014Wouldn't it be great to have a crystal ball to see into the future?You could know when the next market crash will be, ...
Buybacks Instead of Capital Investment - Ahead of Wall StreetJanuary 28, 2014Hard to make sense of the fact that companies would consider it prudent to invest in their own sharesinstead of their businesses.
Capital Spending vs. Buybacks - Ahead of Wall StreetDecember 24, 2013If the Durable Goods report is a sign of things to come, then it would be a material improvement in the economic outlook.
Pharma & Biotech Stock Outlook - Dec 2013 - Industry OutlookDecember 3, 2013Pharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
Gilead Sciences Leads In Rising Short Interest Among BiotechsNovember 12, 2013Among leading biotech and emerging pharmaceutical companies, the number of shares sold short in Alexion Pharmaceuticals ...
Fed Stays on Sidlines, For Now - Ahead of Wall StreetOctober 29, 2013he Fed isn???t expected to make any changes this time, with Taper not expected to start till April 2014.
Q2 Earnings Season Winding Down - Earnings TrendsAugust 1, 2013Q2 Earnings Season Winding Down - Earnings Trends
Better Margins Can't Hide Merck's Growth ChallengesJuly 30, 2013Merck's near-term growth is looking weak, but margin improvements and an underestimated pipeline could offer upside.
Tentative Markets Ahead of Big Data - Ahead of Wall StreetJuly 30, 2013Markets are waiting for looking for confirmation of improved
Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry OutlookJuly 30, 2013Pharma & Biotech Stock Outlook - July/Aug 2013 - Industry Outlook
Wall Street Happy To Hum La AbbVie En RoseJuly 26, 2013AbbVie's pipeline is better than some think, but valuation is no particular bargain right now.
Weak Earnings Growth Outside Finance - Earnings TrendsJuly 25, 2013Weak Earnings Growth Outside Finance - Earnings Trends
Bull of the Day: Medivation (MDVN) - Bull of the DayJuly 25, 2013Bull of the Day: Medivation (MDVN) - Bull of the Day
Drugs Driving JNJ, With Slow Progress In Devices And ConsumerJuly 17, 2013JNJ is getting great performance out of its drug business, but the remainder still lags.
Mylan Faces Aptalis Challenge - Analyst BlogJuly 15, 2013Mylan has been sued by Aptalis Pharma
Stock Market News for July 15, 2013 - Market NewsJuly 15, 2013Benchmarks posted marginal gains on Friday following better-than-expected results of few banking companies.
BMY/Pfizer Seek to Expand Eliquis Label - Analyst BlogJuly 12, 2013Bristol-Myers Squibb Company and partner Pfizer announced that their supplemental New Drug Application for Eliquis has been ...
VIVUS Inks Deal on Spedra - Analyst BlogJuly 11, 2013VIVUS announced that it has entered into a license and commercialization in addition to a supply agreement for Spedra with ...
Encouraging Data on Portola's PRT4445 - Analyst BlogJuly 9, 2013Portola Pharmaceuticals announced positive results from a phase II study evaluating PRT4445.
Mylan Notches Patent Court Fight Win - Analyst BlogJuly 9, 2013Mylan received a favorable verdict in a patent infringement case with Sunovion.
Impax Challenges Toviaz Patent - Analyst BlogJuly 5, 2013Impax Laboratories announced that it is looking to get its generic version of Toviaz tablets approved in the US.
New Data on Biogen's Alprolix - Analyst BlogJuly 3, 2013Alprolix is currently under FDA review with a response expected by year end.
Data on Roche's Herceptin - Analyst BlogJuly 3, 2013Roche recently announced that CHMP in Europe has given a positive opinion on a subcutaneous formulation of Herceptin for ...
Positive Data on BMY/ Pfizer's Eliquis - Analyst BlogJuly 3, 2013Bristol-Myers and Pfizer presented encouraging data on Eliquis.
Sanofi's Lemtrada Gets CHMP Backing - Analyst BlogJuly 1, 2013The Committee for Medicinal Products for Human Use recommended the approval of Lemtrada
Mylan Inks Deal - Analyst BlogJuly 1, 2013Mylan Inc. signed a distribution agreement with Zyomyx.
Stock Market News for July 1, 2013 - Market NewsJuly 1, 2013Benchmarks ended a three day gaining streak on Friday as fears of the Federal Reserve scaling back the bond buying program ...
Benzinga Market Primer: Friday, June 28: End of Month EditionJune 28, 2013Futures Rise On Better Japan DataU.S. equity futures rose in early pre-market trade following lots of stronger than expected ...
VIVUS' Spedra Gets EU Approval - Analyst BlogJune 27, 2013VIVUS announced that the European Commission has cleared Spedra
Novartis' Sandoz Progresses with Biosimilars - Analyst BlogJune 26, 2013Novartis announced that its generic arm, Sandoz, has initiated a phase III study for its biosimilar version of Amgen's (AMGN) ...
Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...June 26, 2013Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
Protalix and Brazil Health Ministry Ink Deal - Analyst BlogJune 25, 2013Protalix signed a supply and technology transfer agreement with Fiocruz for Uplyso for the treatment of Gaucher disease.
ViroPharma and Other Biotech Stocks Recommended by Oppenheimer ...June 24, 2013Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new ...
Encouraging Data on Novartis Candidate - Analyst BlogJune 10, 2013Novartis (NVS) recently released encouraging data on its pipeline candidate, LDK378, from a phase I study.
Positive Data on Novartis' Afinitor - Analyst BlogJune 7, 2013Novartis recently announced positive results on Afinitor, from a phase III trial, BOLERO-3 (Breast cancer trials of OraL ...
Make Money From SpinoffsJune 4, 2013According to Barrons, 15 spinoffs have taken place in 2013 through the end of May, 50% more than last year. It seems all ...
Alnylam Basking In Orphan Drug AttentionMay 28, 2013Alnylam has already seen a big run, but clinical success could bring even more gains.
Coty Readies IPOMay 28, 2013Fragrance maker Coty filed a registration statement amendment May 28 that sees it raising as much as $1.2 billion from its ...
Amgen Chased By The BubbleMay 8, 2013Amgen really needs the pipeline to come through to support this valuation.
Agilent Misses, Guidance Disappoints - Analyst BlogFebruary 15, 2013Agilent Technologies' A) fiscal first quarter earnings per share of 63 cents missed the Zacks Consensus Estimate by 4 cents, ...
Agilent Unit & Pfizer Collaborate - Analyst BlogFebruary 14, 2013Dako, an Agilent Technologies A) subsidiary, has entered into an agreement with Pfizer Inc. (PFE) related to the development ...
Data on Biogen Hemophilia Candidates - Analyst BlogFebruary 11, 2013Biogen Idec (BIIB) and partner, Swedish Orphan Biovitrum recently presented encouraging data on their hemophilia candidates, ...
Protalix Exploring Options - Analyst BlogFebruary 7, 2013Protalix BioTherapeutics, Inc. (PLX) recently confirmed that it has hired Citigroup, Inc. C) to explore strategic options. ...
Favorable Ruling for Pfizer - Analyst BlogFebruary 7, 2013Pfizer Inc. (PFE) recently received a favorable ruling in its patent infringement case against Actavis, Inc. (ACT) for Rapamune. ...
Zoetis Commences Trading - Analyst BlogFebruary 4, 2013Zoetis Inc. (ZTS), the former Animal Health business of Pfizer Inc. (PFE), started trading on the New York Stock Exchange ...
Positive Data on Spectrum Candidate - Analyst BlogJanuary 29, 2013Spectrum Pharmaceuticals (SPPI) recently announced safety findings from the phase II BELIEF study on belinostat. Spectrum ...
MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst InterviewsJanuary 29, 2013We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
MedTech Industry Stock Outlook - Jan 2013 - Industry OutlookJanuary 29, 2013We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
FDA to Review Sanofi's Lemtrada - Analyst BlogJanuary 29, 2013Sanofi's (SNY) subsidiary, Genzyme, recently announced that the US Food and Drug Administration (FDA) has accepted the marketing ...
Market News Fails to Disappoint - Analyst BlogJanuary 29, 2013As the first FOMC meeting of 2013 gets underway today, it is perhaps appropriate to acknowledge the Fed's contribution to ...
Ahead of Wall Street - January 29, 2013 - Ahead of Wall StreetJanuary 29, 2013Tuesday, January 29, 2013 As the first FOMC meeting of 2013 gets underway today, it is perhaps appropriate to acknowledge ...
Generic Launch at Dr. Reddy's - Analyst BlogJanuary 28, 2013Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of Merck & Co's (MRK) Singulair oral ...
CHMP Positive on Pfizer's Bosutinib - Analyst BlogJanuary 23, 2013Pfizer Inc. (PFE) recently received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal ...
Patent Extension at Spectrum Pharma - Analyst BlogJanuary 22, 2013The US Patent and Trademark Office (USPTO) recently extended the patent covering Spectrum Pharmaceuticals' (SPPI) Fusilev ...
SNY's Allerject Launched in Canada - Analyst BlogJanuary 22, 2013Sanofi (SNY) recently announced that its epinephrine injection, Allerject, is available in Canada for the emergency treatment ...
Bristol-Myers Preview: Will it Miss? - Analyst BlogJanuary 21, 2013Bristol-Myers Squibb Company (BMY) is scheduled to release its fourth-quarter 2012 results before the opening bell on Thursday, ...
Management Expands at AstraZeneca - Analyst BlogJanuary 17, 2013AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At the same ...
Should Third Quarter Results From Forest Laboratories Worry Investors?January 17, 2013Forest Labs' miss doesn't seem like a thesis-changing event.
Data on Novartis' Afinitor - Analyst BlogJanuary 14, 2013As per recent data published in The Lancet, Novartis' (NVS) cancer drug, Afinitor (everolimus), helped reduce the tumor size ...
Setback for ArQule, Shares Fall - Analyst BlogJanuary 14, 2013ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib ...
Isis Pharma Updates on its Pipeline - Analyst BlogJanuary 11, 2013Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
Catalyst-Filled 2013 for Onyx - Analyst BlogJanuary 9, 2013Onyx Pharmaceuticals, Inc. (ONXX) recently provided an update on its performance in 2012 and its plans for 2013. Kyprolis ...
US Approval for Eliquis - Analyst BlogDecember 31, 2012Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer Inc. (PFE) received some encouraging news when the US Food ...
Bayer Submits Regorafenib in Japan - Analyst BlogDecember 28, 2012Bayer Yakuhin Ltd., the Japanese subsidiary of Bayer AG (BAYRY), submitted a marketing authorization application for regorafenib ...
Japanese Approval for Eliquis - Analyst BlogDecember 27, 2012Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer Inc. (PFE) received some encouraging news with the Japanese ...
Glaxo/THRX's COPD Candidate Advances - Analyst BlogDecember 20, 2012GlaxoSmithKline (GSK) and Theravance, Inc. (THRX) recently announced that they have submitted a marketing application to ...
Stock Market News for December 20, 2012 - Market NewsDecember 20, 2012Talks between Democrats and Republicans on the Fiscal Cliff issue took a negative turn, dragging the benchmarks into the ...
An End to Drug Patent Woes? - Analyst BlogDecember 14, 2012The US Supreme Court will soon hear a case which will determine whether "pay-for-delay" agreements between drug manufacturers ...
Lilly Plans Trial for Solanezumab - Analyst BlogDecember 13, 2012Eli Lilly (LLY) recently provided an update on its plans for its Alzheimer's disease candidate, solanezumab. The company ...
Merck's Alzheimer's Drug Progresses - Analyst BlogDecember 10, 2012Merck (MRK) recently moved its Alzheimer's disease candidate, MK-8931, into a phase II/III study (EPOCH). The study will ...
Pharma & Biotech Stock Outlook - Dec 2012 - Zacks Analyst InterviewsDecember 6, 2012The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
Pharma & Biotech Stock Outlook - Dec 2012 - Industry OutlookDecember 6, 2012The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The ...
NVS Discusses Data Readout Plans - Analyst BlogNovember 29, 2012Swiss pharmaceutical giant Novartis (NVS) recently announced that it intends to present key data from studies in patients ...
Elan Starts Phase II AD Study - Analyst BlogNovember 28, 2012Elan Corporation (ELN) recently initiated a phase II study on ELND005 (Study AG201) for the treatment of agitation/aggression ...
BASF's Deal For Pronova Shows The Importance Of Good NutritionNovember 23, 2012BASF ties up another high-grade fish oil company in Pronovna, adding to the recent rise in popularity for the fish oil space.
Another Generic from Dr. Reddy's - Analyst BlogNovember 23, 2012Dr. Reddy's Laboratories (RDY) recently launched its generic version of Pfizer's (PFE) pulmonary arterial hypertension (PAH) ...
BMY/PFE's Eliquis Cleared in the EU - Analyst BlogNovember 21, 2012Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer Inc. (PFE) received some encouraging news with the European ...
Pfizer's Lyrica Scores in Study - Analyst BlogNovember 21, 2012Pfizer Inc. (PFE) recently announced positive top-line data on its once-daily formulation of Lyrica (pregabalin). Results ...
Pipeline Progress at Novartis - Analyst BlogNovember 14, 2012Switzerland-based pharmaceutical company, Novartis AG (NVS) recently announced positive data on its pipeline candidate, QVA149 ...
EU Nod for Novartis' Votubia - Analyst BlogNovember 13, 2012The European Commission (EC) recently approved Swiss pharmaceutical giant Novartis' (NVS) Votubia to treat adults suffering ...
Weak Quarter from Auxilium Pharma - Analyst BlogNovember 8, 2012Auxilium Pharmaceuticals, Inc. (AUXL) reported a loss of 21 cents per share in the third quarter of 2012, wider than the ...
Bayer Buys Schiff Nutrition International: Winners All AroundNovember 7, 2012Bayer announced November 2 that it's buying Schiff for $1.2 billion to bulk up its consumer business.
Teva Likely To Tread Water Ahead Of New StrategyNovember 5, 2012Teva has restructuring and growth opportunities, but the risk is still elevated.
Stock Market News for November 2, 2012 - Market NewsNovember 2, 2012Benchmarks finished in the green on the first trading day of November banking on positive consumer confidence and private ...
Glaxo Misses on Both Counts - Analyst BlogNovember 1, 2012GlaxoSmithKline (GSK) reported third quarter 2012 earnings of 71 cents per American Depository Share (ADS), well below the ...
Economic Data Deluge Today - Analyst BlogNovember 1, 2012We have a flood of economic and earnings reports this morning, but the focus will be on the labor market today ahead of the ...
Ahead of Wall Street - Nov. 1, 2012 - Ahead of Wall StreetNovember 1, 2012Thursday, November 1, 2012 We have a flood of economic and earnings reports this morning, but the focus will be on the ...
Priority FDA Review for Stivarga - Analyst BlogOctober 31, 2012Recently, the HealthCare unit of Bayer (BAYRY) announced that its oncology drug Stivarga (regorafenib) will be reviewed on ...
Solid Quarter at Dr. Reddy's - Analyst BlogOctober 31, 2012Dr. Reddy's Laboratories (RDY) reported second quarter fiscal 2013 earnings per American Depositary Share (ADS) of 50 cents, ...
Markets Stay Closed, Some Earnings Delays - Analyst BlogOctober 30, 2012Markets remain closed for a second day on Tuesday due to Hurricane Sandy, with published accounts putting the preliminary ...
Ahead of Wall Street - October 30, 2012 - Ahead of Wall StreetOctober 30, 2012Tuesday, October 30, 2012 Markets remain closed for a second day on Tuesday due to Hurricane Sandy, with published accounts ...
Loss at Elan Wider than Expected - Analyst BlogOctober 25, 2012Elan Corporation's (ELN) loss of 5 cents per share (excluding special items) for the second quarter of 2012 was wider than ...
Generic Plavix Hurts Bristol-Myers - Analyst BlogOctober 24, 2012Bristol-Myers Squibb Company's (BMY) second quarter 2012 earnings (excluding special items) of 48 cents per share fell short ...
NVO Looking to Expand Portfolio - Analyst BlogOctober 17, 2012Denmark-based Novo Nordisk (NVO) is seeking regulatory approval for its hemophilia A candidate turoctocog alfa (NN7008). ...
Drugs Have Moved J&J On To A New PhaseOctober 17, 2012J&J is back on a growth track, but the device business needs fixing.
Stock Market News for October 17, 2012 - Market NewsOctober 17, 2012Better-than expected quarterly results combined with a couple of positive domestic reports guided the benchmarks into the ...
Abbott Reports Encouraging HCV Data - Analyst BlogOctober 16, 2012Abbott Laboratories (ABT) recently announced promising data from the phase IIb Aviator trial evaluating the combination of ...
Stock Market News for October 16, 2012 - Market NewsOctober 16, 2012Strong September retail sales data coupled with better-than-expected quarterly results by Citigroup drove the benchmarks ...
Lilly Up on Alzheimer's Data - Analyst BlogOctober 9, 2012Shares of Eli Lilly and Company (LLY) reached a 52-week high of $50.94 on Monday with the company reporting full results ...
How to Invest If Romney Wins the ElectionOctober 3, 2012Though President Barack Obama leads the latest polls, it's too soon to write Mitt Romney off as a winning candidate. And ...
Bayer's Stivarga Gains Approval - Analyst BlogSeptember 28, 2012The HealthCare unit of Bayer (BAYRY) recently announced that the US Food and Drug Administration (FDA) has cleared its oncology ...
New Target Date for BMY/PFE's Eliquis - Analyst BlogSeptember 27, 2012The US approval process of Bristol-Myers Squibb Company/Pfizer Inc.'s (BMY/PFE) anti-clotting drug Eliquis (apixaban) is ...
3 ETFs In Focus As Election NearsSeptember 27, 2012ETFs have earned the respect of countless investors as viable financial instruments well suited as core building blocs for ...
Glaxo Back on a Neutral Path - Analyst BlogSeptember 25, 2012GlaxoSmithKline plc (GSK) performed disappointingly in the second quarter of 2012, missing the Zacks Consensus Estimate both ...
CHMP in Favor of Lilly's Cialis - Analyst BlogSeptember 25, 2012Eli Lilly and Company's (LLY) Cialis (tadalafil) recently received a positive opinion from the Committee for Medicinal Products ...
CHMP in Favor of BMY/PFE's Eliquis - Analyst BlogSeptember 24, 2012Recently, Bristol-Myers Squibb Company (BMY) and partner, Pfizer Inc. (PFE) received some encouraging news with the European ...
CHMP Positive on Novartis' Votubia - Analyst BlogSeptember 24, 2012Switzerland-based pharmaceutical company, Novartis AG (NVS) recently announced that the Committee for Medicinal Products ...
Dr. Reddy's Launches Generic Amoxil - Analyst BlogSeptember 21, 2012Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of GlaxoSmithKline's (GSK) Amoxil (amoxicillin) ...
CPIX Reports Encouraging Data - Analyst BlogSeptember 20, 2012Cumberland Pharmaceuticals Inc. (CPIX) recently announced encouraging top-line results from a phase IV study on Caldolor ...
Pfizer-Hisun JV Launched - Analyst BlogSeptember 18, 2012Pfizer (PFE) and Chinese pharmaceutical company, Zhejiang Hisun Pharmaceuticals, recently announced the launch of their joint ...
New Data on Merck's Insomnia Drug - Analyst BlogSeptember 17, 2012Merck & Co. (MRK) recently presented new data on its insomnia candidate, suvorexant, at the 21st Congress of the European ...
Perrigo Eyes Pet Care Market - Analyst BlogSeptember 17, 2012In a bid to diversify its business into the pet care space, Perrigo Company (PRGO) inked a deal to buy substantially the ...
AstraZeneca in Neutral Lane - Analyst BlogSeptember 14, 2012We are maintaining our Neutral recommendation on AstraZeneca (AZN) with a target price of $49.00. The stock carries a Zacks ...
Abbott-Astellas Collaborate - Analyst BlogSeptember 13, 2012Abbott Laboratories (ABT) recently announced that it is collaborating with Astellas Pharma Global Development for a phase ...
Sanofi MS Drug Gets Approval - Analyst BlogSeptember 13, 2012Sanofi (SNY) and its subsidiary Genzyme recently announced that their oral candidate for relapsing forms of multiple sclerosis ...
Dr. Reddy's Launches Generic Toprol - Analyst BlogSeptember 12, 2012Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of AstraZeneca's (AZN) hypertension drug ...
Pipeline Progress at CELG, Shares Up - Analyst BlogSeptember 7, 2012Recently, Celgene Corporation (CELG) announced encouraging data from two phase III studies (PALACE-2, PALACE-3), which evaluated ...
Pfizer's Orphan Drug Approved - Analyst BlogSeptember 6, 2012Pfizer Inc. (PFE) received approval for another oncology candidate recently. Bosulif (bosutinib) gained US Food and Drug ...
EC Approves Pfizer's Inlyta - Analyst BlogSeptember 5, 2012Pfizer Inc. (PFE) recently announced European Commission (EC) approval of its renal cell cancer drug, Inlyta (axitinib). ...
Bayer Seeks Regorafenib Approval - Analyst BlogSeptember 5, 2012The HealthCare unit of Bayer (BAYRY) recently submitted a new drug application (NDA) with the US Food and Drug Administration ...
AstraZeneca's Zinforo Gets EC Nod - Analyst BlogAugust 30, 2012AstraZeneca (AZN) recently announced that the European Commission (EC) has approved Zinforo (ceftaroline fosamil) for treating ...
AstraZeneca Recruits New CEO - Analyst BlogAugust 29, 2012AstraZeneca (AZN) recently announced that Pascal Soriot has been recruited as the new Chief Executive Officer (CEO) of the ...
Lilly's Alzheimer's Candidate Fails - Analyst BlogAugust 28, 2012Eli Lilly and Company (LLY) recently announced much awaited top-line results on Alzheimer's disease candidate, solanezumab ...
Sanofi's Lemtrada US Filing Update - Analyst BlogAugust 28, 2012Sanofi's (SNY) subsidiary, Genzyme, recently announced that the US Food and Drug Administration (FDA) has issued a refuse-to-file ...
Bad News for Bristol-Myers - Analyst BlogAugust 27, 2012Bristol-Myers Squibb Company (BMY) recently suffered a pipeline setback when it announced the discontinuation of the development ...
Sanofi's Auvi-Q Gets FDA Nod - Analyst BlogAugust 17, 2012Sanofi (SNY) recently gained US Food and Drug Administration approval for Auvi-Q (epinephrine injection) for the emergency ...
Watson Pharma Sues FDA - Analyst BlogAugust 17, 2012Watson Pharmaceuticals Inc. (WPI) recently announced the filing of a lawsuit against the US Food and Drug Administration ...
MWI Vet-IDEXX Bond 'Non-Exclusive' (revised) - Analyst BlogAugust 13, 2012MWI Veterinary Supply, Inc. (MWIV), a worldwide distributor of animal health products to veterinarians, has formed a revised ...
MWI Vet-IDEXX Bond 'Non-Exclusive' - Analyst BlogAugust 10, 2012MWI Veterinary Supply, Inc., (MWIV), a worldwide distributor of animal health products to veterinarians, has formed a revised ...
Loss at Vivus Wider-Than-Expected - Analyst BlogAugust 10, 2012Vivus Inc.'s (VVUS) second quarter 2012 loss of 24 cents per share was wider than the Zacks Consensus loss Estimate of 23 ...
Dr. Reddy's Expands Portfolio - Analyst BlogAugust 9, 2012Dr. Reddy's Laboratories (RDY) recently announced the launch of its generic version of Merck & Co's (MRK) blockbuster asthma ...
Pfizer & JNJ End Bapineuzumab IV - Analyst BlogAugust 7, 2012Pfizer, Inc. (PFE) recently announced disappointing late-stage results on intravenous (IV) bapineuzumab. Bapineuzumab is ...
Company News for August 1, 2012 - Corporate SummaryAugust 1, 2012" BP plc (ADR) (NYSE:BP) posted second quarter earnings per share of $1.16, missing the Zacks Consensus Estimate of $1.46 ...
Huntington Launches Sector Rotation ETF (HUSE)July 30, 2012Huntington, fresh off its initial foray into the ETF industry in June, has doubled the size of its lineup with the launch ...
Portfolio Pruning 101July 27, 2012MoneyShow's Tom Aspray takes an in-depth look at his successful Charts in Play Portfolio, as he looks to take profits on ...
Amgen Beats, Raises Guidance - Analyst BlogJuly 27, 2012Amgen (AMGN) continued its strong performance in 2012 with second quarter earnings coming in at $1.82 per share, 31 cents ...
4 Dividend ETFs With Higher Yields Than LQDJuly 24, 2012Once upon a time, the conventional wisdom was that investors should hold stocks as a source of long-term capital appreciation ...
Promising Quarter for Dr. Reddy's - Analyst BlogJuly 23, 2012Dr. Reddy's Laboratories (RDY) reported first quarter fiscal 2013 earnings per American Depositary Share (ADS) of 40 cents, ...
Earnings Preview: Bristol-Myers - Analyst BlogJuly 23, 2012Biopharmaceutical giant Bristol-Myers Squibb Company (BMY) is all set to unveil its second quarter 2012 results before ...
Lyrica Court Win for Pfizer - Analyst BlogJuly 20, 2012Pfizer Inc. (PFE) recently received good news with the United States District Court for the District of Delaware upholding ...
Dr. Reddy's Launches Generic Lipitor - Analyst BlogJuly 19, 2012Yet another generic version of Pfizer's (PFE) cholesterol drug, Lipitor (atorvastatin calcium), entered the market recently ...
AZN to Restructure Operations - Analyst BlogJuly 18, 2012AstraZeneca PLC's (AZN) global biologics division, MedImmune, is set to streamline its infectious disease and vaccines research, ...
Good News for Celgene's Pipeline - Analyst BlogJuly 16, 2012Celgene Corporation (CELG) recently announced positive top-line results on its candidate apremilast from a phase III study ...
Merck KGaA's Erbitux Disappoints - Analyst BlogJuly 10, 2012Merck KGaA (MKGAF) recently announced that Erbitux failed to achieve its primary endpoint in the phase III EXPAND trial, ...
What Patent Cliff? Pharma ETFs Continue to Surge - ETF News And ...July 10, 2012For at least the past few years, investors in the health care segment have been focused in on big pharma and the segment's ...
GolinHarris Acquires Virgo Health - Analyst BlogJuly 6, 2012GolinHarris, a division of Interpublic Group (IPG) intends to acquire Virgo Heath, an independent UK-based Healthcare Communications ...
4 Market-Leading Sectors for Q3July 3, 2012The technical action in these four sectors suggests that investors should look here as the markets enter the second half ...
The Most Overbought Dow StocksJuly 3, 2012Despite large first-quarter gains, two big Dow stocks show strong monthly chart formations and are worthy of new buying. ...
June's Worst Dow StocksJune 30, 2012As has been duly noted, the Dow Jones Industrial Average was a juggernaut of an index during the month of June, but naysayers ...
Bristol-Myers/Pfizer get CRL - Analyst BlogJune 28, 2012Recently, Bristol-Myers Squibb (BMY) and partner, Pfizer Inc. (PFE), suffered a setback when the US Food and Drug Administration ...
Health Care ETFs in Focus on Obamacare Supreme Court Decision ...June 27, 2012In what looks to be the biggest Supreme Court decision since Bush v. Gore, the highest court in the land will give its opinion ...
Good News for Endo's Pain Portfolio - Analyst BlogJune 15, 2012Endo Health Solutions (ENDP) recently announced that the transition of the company's Opana ER franchise to the new version, ...
BMY Presents Positive Data - Analyst BlogJune 6, 2012Bristol-Myers Squibb Company (BMY) recently presented encouraging data from a late-stage study (AMPLE: n=646), which evaluated ...
Bayer's Cancer Candidate Encourages - Analyst BlogJune 6, 2012The HealthCare unit of Bayer (BAYRY) recently announced that its cancer candidate regorafenib fared well in a phase III ...
Dow 30 Stocks With High DividendsJune 1, 2012We combed through the Dow 30 to find some of its highest-yielding stocks.
Treat Stocks Like SavingsMay 15, 2012These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
Wide Moat Research Vs. S&P 500May 11, 2012Comparing the performance of the Wide Moat strategy versus the S&P 500.
Merck Biding Its TimeMay 4, 2012Merck investors are getting paid to wait until top-line trends improve.
Company News for May 02, 2012 - Corporate SummaryMay 2, 2012Company News for May 02, 2012 - Corporate Summary
The 10 Most Overbought Dow StocksMay 1, 2012Their surprising 2011 outperformance has left many big Dow stocks close to overbought conditions, but several strong performers ...
Don't Underestimate Dividends In A RecessionApril 30, 2012Today, businesses that provide the most basic human needs - food and medicine - are paying above-normal rates of return.
5 Easy Ways to Cash In on US DividendsApril 26, 2012If you're outside the US looking in, there are important pros and cons to adding exchange traded funds from America ...
Nestle Almost Never On SaleApril 24, 2012Nestle has a well-earned reputation for excellence and the Street has long been happy to pay a premium for that performance. ...
J&J Sticking TogetherApril 23, 2012There is turnaround potential at J&J as it regains its former glory. The company has decided that operating a diversified ...
5 Dow 30 Stocks With Huge DividendsMarch 21, 2012We combed through the Dow 30 to find some of its highest-yielding stocks.
Treat Stocks Like SavingsMarch 20, 2012These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
Birth Control Subsidies Slashed: Will Big Pharma Take A Hit?March 6, 2012Several states have already slashed birth control subsidies. Learn how this will affect pharmaceutical stocks.
Navellier's Top Dividend PicksMarch 2, 2012Louis Navellier reviews the top dividend-paying stocks in his portfolio, which has an overall yield of over 4%. Louis, ...
Profit-Taking Time for This Drug StockFebruary 29, 2012Use this opportunity to step out of this stock while it's in rally mode, and if you want exposure in the sector, put your ...
5 Dow 30 Stocks With Huge DividendsFebruary 27, 2012We combed through the Dow 30 to find some of its highest-yielding stocks.
Costs Keep The Squeeze On HeinzFebruary 22, 2012Heinz is having difficulties absorbing cost inflation.
Value At Abbott Labs Balances A Lot Of Growth OptimismFebruary 14, 2012Growth expectations may be too high for Abbott.
Treat Stocks Like SavingsJanuary 30, 2012These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
The Long-Term Play In Lab WorkJanuary 16, 2012As drugmakers beef up their pipelines in this world of rising costs, the contract research sector should profit.
The Hot ETF for 2012January 11, 2012Here's a look at the method behind the picking my annual Hot Hand, so even if the pick misfires, at least you can buy into ...
Don't Count Out Healthcare StocksJanuary 6, 2012The healthcare sector remains bogged down in a mire of regulation and dwindling spending.
Slow And Steady ETFs OutperformingJanuary 3, 2012Low volatility ETFs lead the way in 2011.
The War Against Alzheimer's Requires Thinking SmallJanuary 2, 2012A meaningful treatment for Alzheimer's is no longer out of reach. Find out which companies are in the race to find a cure.
2011 In Review - PharmaceuticalsDecember 29, 20112011 was a surprisingly healthy year for drug stocks.
How to Evaluate Global Dividend StocksDecember 22, 2011Dividend yield is the most important factor to use when evaluating investment opportunities, says London-based portfolio ...
5 Dow 30 Stocks With Huge DividendsDecember 22, 2011We combed through the Dow 30 to find some of its highest-yielding stocks.
Treat Stocks Like SavingsDecember 19, 2011These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
2011's Highest Performing DJIA stocksDecember 15, 2011Check out 2011's highest-performing DJIA stocks.
5 Dow 30 Stocks With Huge DividendsNovember 24, 2011We combed through the Dow 30 to find some of its highest-yielding stocks.
Dendreon's Chinese Water TortureNovember 3, 2011Dendreon's Provenge continues to shape up as a major disappointment.
Big Values In Big PharmaNovember 1, 2011The major pharmaceutical firms now represent value. These companies could represent a great income play.
Merck's Penance Has Gone On Long EnoughOctober 31, 2011Merck won't grow fast, but it's quality is undervalued. It's time for investors to reevaluate it.
Abbott Has Benefited From Its DiversificationOctober 25, 2011Why is Abbott deciding to break apart?
Protect On The Downside With J&JOctober 21, 2011J&J trades at a reasonable forward P/E and offers investors downside protection.
High Yielding EquitiesOctober 21, 2011Despite the market volatility, there are still some stocks and ETFs that pay above-average dividend yields.
What Is Walgreen's Next Trick?September 30, 2011Walgreen is doing okay today, but tomorrow is a much bigger question.
The 3 Highest Yielding Pharma StocksSeptember 30, 2011Learn more about three large pharmaceutical companies with the highest current yields.
5 Dow 30 Stocks With Huge DividendsSeptember 28, 2011We combed through the Dow 30 to find some of its highest-yielding stocks.
Vivus Tries A New PathSeptember 21, 2011Vivus takes a more pragmatic approach to getting Qnexa to market.
Endo And Forest – Dumpster-Diving In PharmaSeptember 21, 2011Endo and Forest have problems; however, the valuations seem excessively low.
PerkinElmer Adds High-End Tools To Its BoxSeptember 13, 2011Caliper's rebound comes to an end with a premium take-out by PerkinElmer.
XOMA Rearranges The Deck Chairs One More TimeSeptember 2, 2011XOMA changes management again, but should anybody care?
AAA-Rated Stocks Lead S&P 500August 25, 2011These four blue chips are the only S&P 500 companies with AAA credit ratings, a distinction that shows superior financial ...
Seattle Genetics – And Now The Hard BitAugust 23, 2011Seattle Genetics got a much-needed FDA approval, but the sales ramp could be challenging for the stock.
A Blue-Chip Bargain Hunter's BonanzaAugust 21, 2011Valuations for the large caps are reaching the most attractive levels in decades, writes Paul Larson of Morningstar StockInvestor. ...
Why Insiders Are Buying This Biotech StockAugust 15, 2011There are a number of fundamental developments that have spurred recent purchases of Celgene.
Illumina Gets Capped And CutAugust 4, 2011Illumina's sky-high valuation takes a beating on lower guidance.
3 ETFs to Watch on Debt Deadline DayAugust 4, 2011As markets react to the US debt deal, new corporate earnings reports, and lingering Eurozone debt issues, these three ETFs, ...
July's Dow 30 Winners and LosersAugust 3, 2011See the best and worst performing DJIA stocks from July 2011!
Don't Underestimate Dividends In A RecessionJuly 29, 2011Today, businesses that provide the most basic human needs - food and medicine - are paying above-normal rates of return.
10 Drug Firms to Profit on BiosimilarsJuly 28, 2011Over the next five years, the market for "biosimilars" is forecast to climb to $10 billion worldwide, as many brand-name ...
Top Healthcare Dividend StocksJuly 26, 2011Healthcare stocks are one attractive area in which you can reap dividend income while waiting for the sector to grow.
Drugs Don't Cure All That Ails J&JJuly 20, 2011JNJ's performance is mediocre, as are its investment prospects.
Should Investors Circle Back To Cubist?July 19, 2011Cubist is hitting its targets, but it needs a more exciting pipeline.
Huge Dividends You Can Bank OnJuly 13, 2011Stability and longevity of a dividend are good indicators that the company is focused on returning cash to shareholders.
Getting Drugged On GrowthJuly 6, 2011Valuations look decent for many prescription drug companies.
4 Dow 30 Stocks With Huge DividendsJuly 6, 2011We combed through the Dow 30 to find some of its highest-yielding stocks.
Top Drug StocksJune 30, 2011Recently, three strong factors are driving investors to the drug sector.
Pleasure And Pain For PfizerJune 27, 2011Pfizer sees a new pain pill make it to market and another sent back to the drawing board.
10 Drug Stocks for Safety and YieldsJune 26, 2011Big pharma is an attractive destination for traders and investors looking for safety, yields, and solid value in the current ...
Johnson & Johnson Surrenders In StentsJune 17, 2011JNJ makes a tough and surprising, but ultimately wise, decision.
ETFs To Own And To AvoidJune 13, 2011Investors looking for safety and protection will want to consider the pros and cons of these exchange-traded funds.
5 Stocks At 52-Week HighsJune 9, 2011Five stocks in five different industries at different points in their business cycle. These stocks are hitting highs in their ...
May's Dow 30 Winners and LosersJune 1, 2011See the best and worst performing DJIA stocks from May 2011!
Treat Stocks Like SavingsMay 30, 2011These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during
With Mylan, Maybe Smaller Is BetterMay 6, 2011Mylan is not the biggest or the best, but the valuation here makes it worth a look.
Teva And Cephalon Solve Each Other's ProblemsMay 4, 2011Teva's acquisition of Cephalon is a logical deal that solves problems for each company.
7 Dividend Stocks With Big PayoutsMay 4, 2011Dividend increases are being seen across the board. Find out which stocks are offering the biggest payouts.
Despite The Noise, Abbott Still A ValueApril 25, 2011Abbott has made some curious moves of late, but the value is still there.
Lilly Will Pay Investors For PatienceApril 20, 2011Lilly isn't dynamic, but the value is there.
Stocks OK Despite Debt DowngradeApril 20, 2011Though there was some panic at the start of the week, the stock market may not be in turmoil just yet.
Amarin's Magic PillApril 19, 2011Strong clinical data sends Amarin's stock soaring.
Approval In Hand, Does Xenoport Have The Legs To Run?April 11, 2011Xenoport's pipeline is thin, but Horizant approval buys valuable time.
Merger Monday RecapApril 5, 2011Restaurants, defense, drugs, mining and more made Monday an active day on the M&A front.
Valeant Offers A Princely Sum For CephalonMarch 31, 2011Valeant offers a rare win-win bid for Cephalon.
Treat Stocks Like SavingsMarch 17, 2011These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
Don't Feel Blue About Blue ChipsMarch 10, 2011Today's market valuation has diminished the pool of cheap small caps. Boring large caps, on the other hand, seem more attractive ...
Glaxo And Human Genome Find Rare FDA SuccessMarch 10, 2011With an increasingly scarce FDA approval in hand, HGSI and GSK look to build a blockbuster drug.
PBMs: Making The Most Of GenericsFebruary 3, 2011PBMs stand to benefit from the generic introduction of blockbuster drugs. Has the market fully discounted the opportunity?
Abbott's Next ActJanuary 27, 2011Abbott has significant challenges ahead, but Wall Street seems to assume that the company will lose.
Forest Labs Has Wood To ChopJanuary 19, 2011Will Forest be able to plug a gaping hole in its future revenue?
A Look At The Drug Makers Of 2010December 30, 2010Drug makers faced an uphill fight in 2010 and next year is looking to be just as tough.
Roche Noise May Be A Buyer's Best FriendDecember 22, 2010A spate of bad news may have Roche in great value shape.
InterMune - The Black Knight Of Biotech?December 21, 2010Possible European approval could save the day for this risky biotech.
The Curious And Complicated Case Of MannKindDecember 15, 2010MannKind is a classic high-risk high-reward biotech story.
Can New Leadership Rejuvenate Big Pharma?December 8, 2010Will another new drug company CEO make a difference in a stagnating industry?
November's Best And Worst Performing Dow 30 ComponentsDecember 1, 2010The performance of these Dow 30 stocks was far off market averages.
Expected Increase In Research And DevelopmentNovember 8, 2010Research & Development (R&D) is the key to success in the pharmaceutical industry, but just how much of an impact does it ...
Allergan Winning Wall Street's Beauty PageantNovember 3, 2010Allergan's earnings aren't special, but the stock is basking in Wall Street's love. Is it simply a case of lipstick on a ...
Should Investors Take A Chance On Savient?October 26, 2010Savient's inability to sell itself puts almost everything about the company's value in flux.
BIG Dividends, BIG ReturnsOctober 22, 2010High dividend paying stocks are present in many industries. But do you know how to analyze a balance sheet to ensure that ...
Abbott Labs Showing Meaningful GrowthOctober 21, 2010Abbott might just be the best healthcare stock today.
5 Dow 30 Stocks With Huge DividendsOctober 1, 2010We combed through the Dow 30 to find some of its highest-yielding stocks.
Neogen Is No Bad EggSeptember 28, 2010Food safety scares bring new attention to a proven performer.
Top-Heavy PharmaceuticalsAugust 27, 2010Investors should keep an eye on how much drug companies rely on its top sellers.
Stryker Needs A Growth ResurfacingJuly 22, 2010Stryker is a former growth darling struggling to regain its mojo, but the valuation is enticing.
Investing Like A ContrarianJuly 21, 2010When everyone is selling, it may be the time to buy, so says contrarian investing.
Novartis On The Right TrackJuly 19, 2010With recent sales increases and a solid pipeline, Novartis deserves a spot on the watchlist of anybody looking at Big Pharma.
Cancer Vaccines Continue To Show PromiseJuly 7, 2010Dendreon has put cancer vaccines back in the spotlight, but can they live up to their hype?
What Ails Amgen?June 30, 2010Amgen is being treated like just another Big Pharma laggard, but analysis suggests there is more growth potential here.
Investing In The Adspend PortfolioJune 28, 2010Does advertising spending predict stock returns? Find out here.
3 Large Caps To WatchJune 25, 2010A low P/E is not the only reason to consider these large, high-quality businesses.
Pharmaceuticals With Big ReturnsJune 22, 2010These intriguing Pharmaceuticals currently have big returns.
Stocks That Protect Against DeflationJune 21, 2010Although recent data suggests prices may be falling, inflation may still take over in the long term due to the excess liquidity ...
Big Pharma's On SaleJune 4, 2010Stocks of some of the large pharmaceutical companies are now available at attractive prices.
A Big Deal For Biotechs - ASCOMay 26, 2010ASCO is a major event for the pharmaceutical and biotech industry, and these stocks could shine in the limelight.
Will Adaptive Design Change The BioPharma World?May 13, 2010Adaptive design is an idea whose time has come, and investors in biotechs and pharmaceuticals should stand to benefit.
Drug Companies With Tasty MedicineMay 7, 2010Merck is just one of the drug companies offering up tantalizing earnings per share.
Relief With Bristol-Myers SquibbMay 6, 2010BMY's strong reaction after first-quarter earnings seems more like relief, as the company still has many challenges to surmount.
Pfizer Delivers A Healthy QuarterMay 6, 2010Despite forecasting adjusted earnings of over $2 a share for 2010, Pfizer shares remain at $17.
GlaxoSmithKline On SimmerApril 30, 2010Glaxo's earnings look powerful, but is this really a top idea in the pharma sector?
Forest Labs Is Green With CashApril 16, 2010Look beyond the trees and at the entire Forest, and what you see is a great risk reward opportunity.
Small Med-Tech Names You Should KnowApril 15, 2010These three med-tech names aren't well-known by most investors, but they should be.
Pharmaceutical Profits That Aren't For The DogsMarch 15, 2010Merck and Sanofi-Aventis recently combined their animal health businesses, lending further evidence to the notion that this ...
5 Reasons To Love Greenlight Capital ReMarch 11, 2010David Einhorn, noted investor, is Chairman and largest shareholder of this Cayman Island reinsurance company.
Dow Jones Industrials Play The Share Buyback GameMarch 10, 2010A look at five companies from the Dow Jones Industrial Average that repurchased stock in 2007 and how they've done since.
4 U.S. Companies With High Currency ExposureFebruary 24, 2010The U.S. dollar has been strengthening against the euro which is a bad sign for the U.S. exporters as the goods become more ...
Drug Stocks That Deserve A Closer LookFebruary 19, 2010Pharmaceutical stocks have a bright future, and one of my top choices in the space is Merck, which recently released quarterly ...
Several Giants Set To ReportFebruary 1, 2010These big companies have yet to report earnings - and it will be worth it to hear.
Let's Play The Dow Dividend GameJanuary 29, 2010These three companies are strong alternatives to Dow dividend payers.
There's Nothing Generic About the ProfitsJanuary 27, 2010Any healthcare reform will include severe cost cutting. Giving your portfolio a dose of generic-dug makers will help you ...
Forest Labs' Oh-So-Healthy Balance SheetJanuary 26, 2010This company has a pristine capital structure and a stockpile of cash, but the best part is that its stock is cheap.
Excellent Dividend Prospects In 2010January 7, 2010Today's best businesses are historically high dividend yields, and they shouldn't be ignored in 2010.
Playing Copenhagen With Our Climate LeadersJanuary 4, 2010With the outcome of the climate meeting uncertain, bet on companies that are already taking steps to reduce their emissions.
2009's "Dogs of the Dow"December 31, 2009Was there any bite to the Dogs of the Dow strategy last year?
A Look Back On Deals In 2009December 24, 20092009 was an exciting year for mergers, buyouts, industry consolidation plays and hostile takeover attempts.
Why Today's Market Dictates PessimismNovember 18, 2009Investing as if the markets can only go up is a recipe for disaster, while embracing pessimism will keep you in the game.
Treat Stocks Like SavingsOctober 28, 2009These sensible stocks are likely to provide consistent returns, and would have beaten many professional picks during the ...
Bears Are Still Growling On Wall StreetSeptember 1, 2009Not every investor is optimistic about the economy, and this attitude shows in an examination of the latest data on short ...
A Quiet Quarter For Berkowitz's FairholmeAugust 19, 2009During the second quarter of 2009, Fairholme's quarterly 13F filing showed a relatively quiet quarter for Fairholme.
High Yield Bets For The Conservative InvestorJuly 24, 2009High dividends and long-term dependability make it worth getting involved with these companies.
5 Big Stocks: The Rest Of The Earnings StoryJuly 24, 2009Earnings aren't the only thing worth reviewing. Here we look at highlights from PepsiCo, Pfizer, Boeing, Overstock and others.
Merck Unloved, But Not For LongJuly 23, 2009Merck's release was received without fanfare, but this solid company deserves another look.
A Trio Of High Yielders With Strong Cash PositionsJuly 21, 2009Here are some safe dividends with a 5% dividend or more, a rarity these days for stocks in the S&P 500.
6 Stocks The Pros LikeJuly 17, 2009Watching what professional investors and managers buy is a great way to come up with new stock ideas.
Energizer Keeps Going And GoingMay 15, 2009Energizer Holdings just bought the Edge shaving cream business from SC Johnson & Sons, further diversifying its product offerings.
Don't Underestimate Dividends In A RecessionMay 15, 2009Today, businesses that provide the most basic human needs - food and medicine - are paying above-normal rates of return.
March Mid Cap LosersApril 7, 2009The five worst performing mid cap stocks in March were in a range of industries, and had little in common except missing ...
Biotech Poised to DisappointApril 7, 2009The recent wave of big pharma acquisitions does not live up to hype.
Abbott Labs A Solid Pharma StockApril 3, 2009Abbott Labs has continued to perform solidly as a business and looks poised with its product line to keep going strong.
Why A Merck/Schering Combo Makes SenseMarch 12, 2009The Merck/Schering marriage might be a winning combination for both the companies and investors.
Medical Devices: Cure For Ailing Portfolios?February 27, 2009Find out how these medical device makers may resuscitate your ailing portfolio.
Healthcare Sensitivity According To The DowFebruary 25, 2009Beta is a good measure for investors to use, but it is not a guarantee.
Bristol-Myers Pays Healthy DividendsFebruary 12, 2009Bristol-Myers is among five companies with a great forward annual dividend yield.
Five Dividend Divas For January 15January 15, 2009Dividend-paying stocks can be a boon for investors. Five have a high forward annual dividend yield and may deserve a closer ...
Big Predictions For Big PharmaJanuary 2, 2009As defensive plays, Big Pharma stocks could beat the economic crunch.
One More Step For MannKindDecember 4, 2008This biotech's inhaled insulin seems to work, but will it sell?
Putting The Dow's Fading Pulse In PerspectiveNovember 21, 2008There's a lot of talk about "historic lows" right now. Learn where the Dow's current metrics really stand in history.
Wyeth's Day In CourtNovember 6, 2008Wythe and other drug companies are anxiously awaiting the outcome a product labeling liability case before the U.S. Supreme ...
Aging Population Feeds Global Healthcare DemandOctober 30, 2008Investing in foreign-based healthcare providers is as important as investing in healthcare providers with a global reach.
How Much Vigor In Invitrogen?October 27, 2008Invitrogen is in the right space, but does management have the right plan?
Missing Forest Labs For The TreesOctober 27, 2008Forest Labs is facing a lull in its pipeline, but prior lulls have been good buying opportunities.
Ride The Ups And Downs Of Drug ApprovalOctober 16, 2008The FDA's complex drug approval process provides plenty of volatility for short-term traders to feast upon.
10 Blue Chips On The OutsOctober 8, 2008The market has taken down stocks of all caliber, and these formerly sturdy blue chip stocks are due another look as we wait ...
Coping With Dow 9,000October 7, 2008A breakout of the most resilient components in a falling Dow.
Making Sense Of Cash And ShortsSeptember 29, 2008We examine a group of mutual funds that have large cash positions either from short selling or from asset allocation.
Winners Of The Dow Dog Show For September 3September 3, 2008Let the Dogs of the Dow strategy point you to potential winners. This week's best of breed is DuPont.
Winners Of The Dow Dog Show For August 27August 27, 2008The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to rise. This ...
Winners Of The Dow Dog Show For August 19August 19, 2008The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to go up. Best ...
Winners Of The Dow Dog Show For August 11August 11, 2008The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to go up. Pfizer ...
Amgen's $30 Billion Riddle - Biotech Or Big Pharma?August 7, 2008Amgen's valuations seem too low given recent good news and earnings results. We explore what its new benchmark P/E should ...
Actively Managed ETFsAugust 5, 2008Actively managed ETFs need more time to run before investors can truly determine if passive management is superior.
Winners Of The Dow Dog Show For July 29July 29, 2008The Dogs of the Dow strategy lets investors find undervalued blue chips. This week the best of breed is GE.
Five Dividend Darlings For Monday June 23June 23, 2008You don't have to be a widow or an orphan to appreciate the staying power that dividend-paying stocks add to your portfolio.
Winners Of The Dow Dog ShowJune 20, 2008The Dogs of the Dow strategy involves buying the index's highest yielding stocks and waiting for their prices to go up. We ...
Genentech's Avastin DisappointsApril 11, 2008Genentech released earnings that drew mixed reaction from the Street, but on closer inspection the quarter is a clear miss. ...
Monsanto's Double-Bottom Doubles The FunApril 8, 2008Sometimes a technical trend is so prominent it's impossible to ignore. Monsanto's double-bottom chart could point to a new ...
Novartis' Eye-Catching Deal Won't Add ValueApril 8, 2008Novartis is spreading itself too thin with yet another acquisition - this time for vision specialist Alcon.
Duke Energy Is High Yield RoyaltyMarch 4, 2008Duke Energy's very healthy dividend yield makes it a solid investment as a fixed-income proxy, especially during a flight ...
Johnson & Johnson A Defensive Role Model (JNJ)January 24, 2008JNJ recently reported solid earnings. The stock is nearing the right price for defensive investors seeking no-frills profit ...
Leap Of Faith Healing (MEDX, PDLI, AMLN)August 8, 2007Make the leap with three pharmaceutical companies who require investor courage but could provide a healthy return.
A 20-Year Supply Of Customers (NVS, PFE, AZN)June 7, 2007A look at three medicine makers who are set to cash in on 450 million aging baby-boomers around the globe
Ultimate Headache Relief (BAY)May 17, 2007Investors seeking big pharma exposure often confine themselves to the United States, but the best drug company just might ...
Johnson & Johnson Blows Away Q1 (JNJ)April 20, 2007J&J beat its Q1 consensus number with ease, so where is the stock is headed from here?
Schering's Big Deal (SGP)March 13, 2007An inside look at Schering Plough's big deal to buy Organon BioSciences.
You Gotta Know When To BailFebruary 22, 2007When your stock's prospects take a turn for the worse, bailing out can be the best possible option.
Diversify Your Pharmaceuticals With The Middleman (PPDI)December 12, 2006PPDI proves to be an interesting play on the strong pharmaceutical macro-trend at work in the United States.
Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)November 16, 2006Despite BMY's recent struggles with its Plavix sales, favorable demographics make the stock a good investment to consider.
A Look at Economic Moats - Part 2November 23, 2005In this piece we'll explore different types of economic moats.


text:
Nixon in China Conference Panel II
Panel II at the Nixon in China: A Legacy Revisited conference, sponsored by the UCLA Burkle Center, the UCLA Center for Chinese Studies, and the UCLA Confucius Institute.
Published: Tuesday, March 06, 2012
Panel II
Panel II will assess the enduring legacies of the summit. How have US-China relations evolved, and what role did Nixon's visit, and the ensuing normalization of relations, play in subsequent developments? Looking back, what is the lasting meaning of the summit? Where are US-China relations today - and likely to be tomorrow?
- Susan Shirk, UCSD
- Minxin Pei, Claremont McKenna
- Gen. Wesley Clark
Moderator: Kal Raustiala, UCLA

subset: commoncrawl


text:
22Dre Snowden
Post-Game Notes
Utah State 70, Weber State 6
Countdown To Kickoff - 15 Days: Utah State Concludes Second Scrimmage of Fall Camp With Continued Progress on Both Sides of the Ball
Offensively, Utah State finished the scrimmage with 103 rushing yards on 41 carries and two touchdowns, and was 17-of-33 passing for 159 yards.
UTAH STATE: Will battle for playing time as a nickel defensive back this year... Has arguably the best feet on the team as far as going in and out of breaks.
2012 (RS): Redshirted during his first season at Utah State.
HIGH SCHOOL: Recorded 17 receptions for 265 yards (15.59 ypr) with one touchdown as a prep senior at American Fork (Utah) High School... Also had 19 tackles and two fumble recoveries to go along with one blocked kick... Returned 16 kickoffs for 247 yards (15.44 ypr)... Had four career touchdowns and three career interceptions, to go along with three career blocked kicks.
PERSONAL: in Provo, Utah... One of five children of Will and Courtney Snowden... Undeclared on a college major.


text:
Nutrition Facts label redesign
Dr. Alice Lichtenstein talks with Tufts Now on the first Nutrition Facts label upgrade since its creation 20 years ago.
Another reason to eat oats for heart health
Oats appear to subdue the process associated with the development of atherosclerosis (hardening of arteries).
Lobby Garden
The HNRCA and the Massachusetts Horticultural Society are combining resources to raise vegetables in a new indoor garden in the lobby. Read more about the partnership and the garden by clicking on the image.
The link between coffee and brain health
An interview with Dr. Barbara Shukitt-Hale of the Neuroscience and Aging Lab, on her recent publication "Coffee, but not caffeine, has positive effects on cognition and psychomotor behavior in aging"
Working to delay the onset of type 2 diabetes
The trial, D2d, is the first definitive large-scale trial (in 17 states) to investigate if a Vitamin D supplementation helps prevent or delay type 2 diabetes. Dr. Bess Dawson-Hughes, Director of the Bone Metabolism Laboratory at the HNRCA, is the co-investigator on the project.
Variants in genes can account for macronutrient intake.
Research involving HNRCA scientists shows that variants in genes involved in nutrient metabolism and obesity are associated with macronutrient consumption. Click the image for the abstract.
Volunteers for research studies
We invite people of all ages and backgrounds to participate in exciting nutrition research studies being conducted here at the HNRCA. Learn more about being involved and our current studies…
Welcome to HNRCA
HNRCA Strategic Plan 2011-2015: Meeting Public Health Challenges of Nutrition and Aging
Tufts Nutrition Scientists Unveil MyPlate for Older Adults
Dr. Alice Lichtenstein appointed to the 2015 Dietary Guidelines Advisory Committee


text:
Monday, 25 May 2009
Garter stitch
Just the thing for restoring flagging spirits and an errant knitting mojo.
It is a bank holiday and boilingly hot here, and I'm indoors revising (and photographing last night's knitting). My boyfriend has gone to the Cheese Rolling.
I hope you are enjoying today, whatever you're up to.
5 comments:
- MeowGirl said...
mm, squishy garter. nice color too. what will it grow to be?
that cheese rolling looks delightfully random but rather dangerous.
- May 26, 2009 2:06 pm
- Delly News Blog said...
Nice Post
bus service
bus route
bus tickets
bus routes
bus services
best bus
bus station
travel bus
bus travel
bus timetable
bus transport
online bus tickets
bus india
bus time table
bus terminal
tour bus
local bus
airport buses
bus fares
bus journey
bus stops
buses to airport
bus coach
bus operators
bus price
transport buses
travel by bus
bus tours
bus information
bus rental
buses timetable
indian buses
local buses
bus times
bus operator
bus timetables
cheap bus tickets
bus travel tickets
Vaishnavi Travels
Shree Vijay Travels
Vikas Travels
Aditya Tours And Travels
Shree Sahjanand Travels
Punjab Travels
Shree Hari Travels
Ashwamegh Travels Agency
Intercity Travels
Neeta Tours And Travels
Mahasagar Travels Ltd
Jamnagar Travels Pvt Ltd
Shree Parshwanath Travels
Patel Tours And Travels
Shree Khurana Tours And Travels
HK Travels
Rishabh Travels
Raj Travels
Buses To Virpur
Bus tickets
- October 06, 2009 10:44 am
- Rajasthantraveling said...
This is a very interesting blog and so I like to visit your blog again and again. Keep it up. Goa is a truly divine place. Goa is India's second smallest state by area and fourth smallest state by population. It is located in south west region of India.Goa Tour Packages.
- December 06, 2010 7:29 am
- Networking projects said...
Interesting blog...
- April 12, 2011 2:30 pm
- reshma M said...
Yeah i like to stitch clothes, that to needle works i like it. And i stitched more designs for sarees.
Thank you.....
Reshma M,
Bus Ticket booking online is just a click Away!
- March 08, 2013 7:28 am


text:
924 N Charles St, Baltimore, MD | Directions 2120139.300453 -76.616237
Neighborhoods: Mount Vernon
Closed – went out of business. Couldn't have been that good, huh?
Fell short on wedding reception – We chose a buffet style dinner for our reception. However, a couple of crucial food items we'd requested, namely bread and rice, were absent. One of the appetizers we'd requested be switched out several weeks before was ignored. We actually discovered some of these discrepencies a day or 2 before the wedding, but we were told by the assistant in charge that it was too late to do anything about it. Then when we saw the wedding cake, we were disappointed at how pathetic it looked. It tasted good, but it was nothing like the picture the catering manager showed us it would look like, neither in shape nor in color. The worst part, though, was that numerous guests complained they didn't get enough to eat. A couple of people apparently socialized a little too long and missed out on dinner completely. We heard complaints that the servers were often not at their stations and they ran out of food too quickly and had no replenishments. Many of the wedding party and family got no appetizers, and guests complained that they felt they had to hurry up to get anything to eat. Most people weren't even able to get seconds. I don't believe they had enough food to adequately feed all the guests that were invited. To top it all off, after we brought this to the catering manager's attention a couple of weeks later, he forwarded our complaint on to the owners. Nearly 2 months have passed, and despite several attempts by us to get a response, we've heard nothing from them. We realize now that we probably never will. To be fair, the food was pretty good, and the decor and bar were done very well. But after spending upwards of $10,000 on the catering, one would expect it ALL to be done very well. We expected a lot better service and professionalism. After our experience, I wouldn't recommend the Brass Elephant to anyone for their wedding. It definitely wasn't worth that kind of money to us.
Not bad, but overrated! – A friend and I went here for restaurant week and although the food was pretty good, it's not worth their normal prices. On the plus side our waiter, Lance, was fantastic. Some of the other staff members came off as a little snooty. Our salads came out a bit mushy - as though they had been tossed with the dressing hours before. They were unable to serve the soup without the seafood garnish (shellfish allergy) since the bowls of soup were also made in advance. Our entrees and desserts were nice though.
**I assume the food is prepared fresh to order when there isn't a special event like restaurant week going on, so take this review with a grain of salt.**
Courteous service, elegant surroundings, top notch food. – We ate here on a Saturday night, on a weekend when Valentines day fell midweek. In town for a tattoo convention, I choose the BE based on a review listed here. We had know problem obtaining reservations, and were seated promptly apon arrival (note, no one mentioned a dress code, and it is against their policy to seat anyone in jeans. They were VERY cordial, and simply reminded us of the policy for future reference). The decor is impeccable, classic and reserved without being stuffy or pretentious. Service was top notch, and timed perfectly (our server was from Lithuania, and even brought us a book to browse on her homeland). The food was wonderful, from 1st course (salmon "dome" over potato salad for me, proscuto and figs for him) through the 2nd, which was a perfect Ceasar salad with white anchovies, and roasted butternut squash with a jicima and apple salad. Our 3rd course included roast duck over mushroom risotto and pan juice, and a duet of lamb (lamb croquet, which was the only unremarkable dish, and braised lamb chop served over white beans). Everything was beautifully presented, with portions that were neither minute or overwhelming. We finished our evening with drinks from the bar (top shelf of course) and a newly invented dessert of rissoto cooked in dark chocolate and sereved with raspberries and a chocolate "ciggarette" filled with strawberry paste.
All in all an excellent evening at a reasonable price (under $150) Would definatly visit again.
Sorry, but definitely overrated – My brother, his wife and son, and my significant other and I ate at the BE tonight. We reserved and informed them we had to attend the symphony. We only ordered entrees (to save time), and were glad we did. The kitchen was extremely slow. Also, the table we were seated at was in a tight little corner--far from splendid surroundings, as claimed in their ad. My entree (lamb) was quite good and my SO's dinner (the lamb special) was also good. But the other meals were very ho-hum, and at $28-32 per plate that is simply not good enough. Finally, we had to dash out (given the slow service) and then had to wait in a huge line of people to get our coats. Their system for hanging coats is abysmal. All in all, not a good experience, and definitely not worth the money. We won't be coming back. This is my first review of a restaurant, but I simply had to write it. Sorry, but the BE is WAY over-rated, based on our experience.
Known as a newshounds' watering hole, this regal relic allows patrons to sample the splendor of another era. – The Scene
This Elephant never forgot its past. Under Tiffany skylights, 19th-century mores seep through antique fixtures like a Poe specter returned from the grave. The residential building, designed by the posthumously lauded Lockwood de Forest, found a second life when it was reincarnated as a restaurant, in which impressive drawing rooms (spanning over two floors) and a once-magnificent chandelier recall an earlier, grander time.
The Food
For appetizers, the succulent escargot sits delicately in a Galliano sauce atop equally edible pastry shells. The soups are hearty, nearly a meal unto themselves. But don't skimp: Take the cue from your decadent surroundings. Entrees like duck breast and filet of beef get a kick from sweet potato and confit ravioli, and a horseradish creme fraiche respectively. Afterwards, artistic desserts delight the eyes as well as the tongue.
a Great place – Brass Elephant offers a prix fixe menu ($30); Mondays are 1/2 off Wine prices ! We spent $95 for 2 including a bottle of wine and tip. Great food, atmosphere, beautiful old mansion, free valet parking, what more can you ask for ?
Nice, relaxed Christmas Eve. – We went to the Brass Elephant on Christmas Eve. This was our first time. At first the service was very slow and the waitress was a little rude. However both the bartender and the owner came out and apoligized for the slow service. The food was excellent!!!! The prices were not bad for a nice Baltimore restaurant and the Tusk lounge provides a great place for after dinner drinks. All in all it was a lovely expereince and I would definately recommend it for a special occasion or just a nice dinner.
Even Dad can't complain – This is just about my all-time favorite restaurant in the Baltimore area. The food has been nothing but the best each time I visit. Some may find the small menu a bit restrictive, but "play to your strengths," I always say. Fewer selections allow the chefs to put the amount of time and energy into each dish that it deserves. And you will not be disappointed. In addition, I found the waitstaff go above and beyond the call of duty to see that our every desire was promptly met. From recommending wine and entrees (they honestly told us which dishes they felt may not be up to par) to relating the rich history of the building; I don't think I've ever received better service anywhere. This place even won over my father, and that is a feat in itself. We'll be going back again and again.
View more Reviews for Brass Elephant
Sign in with Facebook Sign in with Facebook to see what your friends are up to!
Do you have a review of Brass Elephant on your blog? If you include the Citysearch image link (shown below) in your post, we'll automatically link to your review from the business profile page. Here's how our Linkback system works:
The Linkback system is free and automatic. It's really that easy.
To link to our business profile page, copy the html below to your web page.


text:
Henry and the Valentine Surprise
Nancy Carlson - Author
Paperback | $6.99 | add to cart | view cart
ISBN 9780142416822 | 32 pages | 23 Dec 2010 | Puffin | 7.99 x 10.00in | 6 - 8 years
Additional Formats:
- Hardcover: $15.99 add to cart
Summary of Henry and the Valentine Surprise Summary of Henry and the Valentine Surprise Reviews for Henry and the Valentine Surprise An Excerpt from Henry and the Valentine Surprise
When Henry and his classmates spot a heart-shaped box on their teacher's desk, they start trying to guess who it's for. The students begin to think Mr. McCarthy has lots of girlfriends when they see him talking to the playground monitor, smiling at the lunch lady, and eating with the French teacher. But when Henry finally asks Mr. McCarthy about the box, it's the class who gets a big surprise!"Carlson's familiar characters provide a sweetly thought-provoking Valentine interlude for the early-elementary set." - Kirkus Reviews
Sign Up
To keep up-to-date, input your email address, and we will contact you on publication
Please alert me via email when:


text:
I previously had given this product a excellent review, but when I went to use it, I found that it dragged on the ground when pulled. This made it very heavy to pull and so I had to go sideways to get anywhere, Good thing it had spinner wheels or I would of had to carry it! did call and send it back to Overstock, which took care of my problem and sent me a return label immediately.
Bag is too small. Narrower than other bags of the same height and height includes wheels. Extra bag is tiny and useless. I returned the bad losing my return shipping costs. Unless you're packing doll's clothes I don't recommend this.
I have not used them yet, but I got the teal and the color is great. Good size, on the smaller side for road trips or carry on. Sturdy construction. Quick shipping
wheels dont roll smoothly, bag is smaller than i expected, guess the wheels are added in the dimensions.
Just a little smaller than I thought it would be. It would have been handy if there had been something to estimate scale.
The spinner wheels weren't as helpful as I had hoped. The bag still tips when you try to roll it.
This was a great price, but treat it with care. Kids played with it and bust the strap.
The bars that shape the suitcase were bent when we opened the package. Had to reshape them (pretty flimsy). Got them for my daughter. She hasn't used them on a flight yet, only overnights. Hopefully they hold up for a while.
Excellent suit case and travel bag size. Suit case has the spinner wheels, which I like.
Usually leaves our warehouse in 1-2 business days. *
Items must be returned in new or unused condition and contain all original materials included with the shipment. More details
FINAL SALE EXCLUSION: Items marked as FINAL SALE are not returnable unless the problem you experience is the result of our error.
Our standard shipping method is ground shipping. We also offer expedited shipping for most items. Your final shipping cost and estimated delivery timeframe will be available at checkout.
Standard shipping details
Expedited shipping details
* For your safety, some orders go through our loss prevention department. If we select your order for this process, we will immediately notify you that there may be up to a 3-day delay on your order.
** Most Oversize orders are delivered within 1-4 weeks. Some orders may take 6 weeks to be delivered.


text:
What is our culture like?Awethans hail from top South African universities and Ivy League Business Schools - with work experience from Fortune 500 Blue Chip corporations and several successful startup ventures under our collective team's belt.
We've gone from a 2-man staff contingent at the beginning of 2012, to over 50 full timers by August 2013... and we're still growing!
This fabulous team of intrapreneurs and entrepreneurs work towards enterprise development and economic stimulation in SA on a daily basis. And we're having fun while doing it...
Video: Awethu Project Work Culture
Video: Incubation Coaches on the job


text:
Headlines: Utility Failed to Plan for Storms; Quinn Calls for Stormproofing
An examination by The Times shows that the Long Island Power Authority -- which serves the Rockaways -- has repeatedly failed to plan for extreme weather. Gov. Cuomo has established a commission to investigate how utilities across the state responded to Sandy. The head of LIPA resigned yesterday.
In the Press...
Council Speaker Urges Stormproofing as Civic Conversation Shifts (NY Times)
Brooklyn Democratic Senator-Elect Simcha Felder Defects to GOP (Daily News)
Refugees Grapple With Hotel Living (Wall Street Journal)


text:
Extract from a confidential report from the British Ambassador, 30th July 1789 (FO 27/32)
You can drag the image around to explore it.
No less than seven Princes of the House of Bourbon & one Princess, have fled in consequence of the troubles, but it is scarcely possible to imagine that the Nation will not, when the violence of it's resentment begins to subside, be desirous of seeing these august Personages reinstated in their respective situations of dignity, especially too upon the motive of policy, when it is considered what immense sums of money will be thrown into the hands of Foreigners, during their absence from this Kingdom.
august - Inspiring awe or admiration; majestic


text:
UNDERNEATH is an evening-length performance that tells a tale of the subconscious mind with the fluid timing of a dream.
12/9 UPDATE: The wonderful Colleen Genuine of Genuine Movement has offered anyone that donates or increases their pledge to $100 or more in the next 3 days a gift certificate for a 1 hour massage. We have been working with Colleen for almost 4 years and she is truly the most intelligent and intuitive body worker we know.
Even though it says sold out, you can still pledge at the $25 level and choose the $10 reward. Sorry for the confusion. We only have a certain number of t-shirts.
UPDATE: Pledge any amount $100 or above between now and December 8 and receive 2 free tickets to our show (12/7 or 12/8), free drinks and snacks from the theatre bar and a vintage Wobbly poster. If you live outside of Portland and can't make it to the show, we will send you a DVD of the performance, a vintage Wobbly poster and a short personal video message, Wobbly style of course!
You can also increase your pledge amount and choose this new reward!
Underneath is a new evening-length work made in collaboration with Wobbly (Yulia Arakelyan and Erik Ferguson), performers Mizu Desierto and Nathan H.G. and musician Roland Toledo. Using a blend of contemporary dance, butoh, theatre and song, Underneath tells a tale of the subconscious with the fluid timing of a dream. Peeling back preconceived notions of beauty and belonging, Underneath reveals an inner landscape of isolation, deformity and domination as four individuals seek the possibility of a love that, perhaps, heals all wounds. This sometimes confrontational sometimes sweet new work manages to crack open the mind without leaving the viewer shattered.
Underneath will be performed in Portland, OR at the Headwaters Theatre November 30-December 8, 2012.
We need your help in the next 30 days to make this show a success! Funds raised through Kickstarter will go toward paying the performers for their creativity, dedication and hours and hours of rehearsal time over the last 2 years. Wobbly is currently working with an amazing musician Roland Toledo, who is creating an original sound score for UNDERNEATH. With your help, we can make sure that the performers and our musician are fairly compensated for their work and dedication to this project.
Our Mission
Risks and challenges Learn about accountability on Kickstarter
This is the first full length production for Wobbly and it has not been without its challenges. We have been through almost two full years of residency at the Headwaters Theatre and one of our original performers relocated and left the project. Working with such a small fringe group and such organic subjective material means no understudies and no substitutions so we had to develop a lot of new material after that. Working with chronic health conditions and disabilities has also left us vulnerable to illness and we lost several weeks along the way to pneumonia, and other health crises. We are in the home stretch now and taking very good care of ourselves in preparation for the big show. Our biggest challenge now is actually navigating and promoting the kickstarter campaign itself. We took a big risk in trying to run a very short 30 day campaign to capitalize on the urgent enthusiasm of our fan base and did not calculate for the time it took to edit the final video, verify a bank account, enter the kickstarter queue, etc. At this late date we are forced to bite our nails and continue to fundraise THROUGH the entire show. We have the generous support of The Headwaters Theatre, Water in the Desert, Regional Arts and Culture Council, Oregon Cultural Trust and Multnomah County Cultural Coalition. Its enough to put the show on but we still have brilliant and deserving performers, sound and lighting artists to pay and we are threatened by our own deep debts. Without the success of this Kickstarter campaign we risk ruining some critical artistic relationships, and we risk not being able to absorb our own debts. Yes, there is always some chance that someone gets sick or injured, or some other catastrophe interferes but we prefer to think that the show is going to go on, we are so close it has to go on. But will we be able to celebrate its success and sow the seeds for the future of the unique and wonderful project? With YOUR support, we will!
Have a question? If the info above doesn't help, you can ask the project creator directly.
pledged of
seconds to go
Project by
Yulia Arakelyan
- First created · 23 backed
- Yulia Arakelyan 633 friends
- wobblydance.com
Pledge $5 or moreYou selected
22 backers
Our unending gratitude and a shout out on facebook.Estimated delivery:
Pledge $10 or moreYou selected
31 backers
All the above plus a Wobbly sticker.Estimated delivery:
Pledge $20 or moreYou selected
22 backers
Our unending gratitude, a shout out on facebook and a show poster signed by the cast.Estimated delivery:
Pledge $25 or moreYou selected
11 backers Limited (9 left of 20)
All the above plus a Wobbly t-shirtEstimated delivery:
Pledge $26 or moreYou selected
10 backers All gone!
A Wobbly t-shirt and a signed poster, a shout-out on facebook and our unending gratitude.Estimated delivery:
Pledge $50 or moreYou selected
18 backers
Our unending gratitude, a shout out on facebook, an UNDERNEATH poster signed by the cast, and a DVD of the performance.Estimated delivery:
Pledge $100 or moreYou selected
5 backers
2 tickets to the show, a poster signed by the cast, a Wobbly sticker, a shout out on facebook and our unending gratitude. MUST PLEDGE BY NOVEMBER 29th if you want to see the show!Estimated delivery:
Pledge $100 or moreYou selected
1 backer
SPECIAL REWARD! Pledge any amount $100 or above between now and December 8 and receive 2 free tickets to our show (12/7 or 12/8), free drinks and snacks from the theatre bar and a vintage Wobbly poster. If you live outside of Portland and can't make it to the show, we will send you a DVD of the performance, a vintage Wobbly poster and a short personal video message, Wobbly style of course!Estimated delivery:
Pledge $200 or moreYou selected
1 backer
A personalized video dance performance from the Wobbly crew, made especially for you! We will also mail you stickers and a signed poster too. If you pledge by November 29th, we will give you 2 free tickets to the show.Estimated delivery:
Pledge $500 or moreYou selected
0 backers
4 tickets to the show, unlimited drinks and snacks from the theatre bar, a poster signed by the cast, and an invitation to hang out with the Wobbly crew after the show or on another date of your choice. Pledge before the show ends on 12/8 for tickets!Estimated delivery:
Pledge $1,000 or moreYou selected
0 backers
We will dance for you! Pick a time, pick a place (must be wheelchair accessible and in Oregon or Washington), invite your friends, make it a party! A performance just for you! We will also give you 4 tickets to the show, a t-shirt and sticker, a signed poster, a DVD, and of course our unending gratitude and a shout out on facebook.Estimated delivery:
Funding period
- (30 days)


text:
personalized christmas ornaments
All Sale Christmas Ornaments have FREE Personalization Too! SHOP OUR SALE>>
When you buy 5 or more items!Learn more >>
- all categories:
- Activities
- Advent Calendars
- African American / Ethnic
- Angel
- Anniversary, Wedding & Engagement
- Baby
- Birthstone
- College and University
- Diannes Gift Ideas
- Easter
- Expecting Moms/Couples
- Fairy Tales and Nursery Rhymes
- Fall and Halloween
- Family
- Food & Drink
- For Her
- For Him
- Glass Ball
- Glass Ornaments
- Graduation
- Grandparents
- Holiday Plaques
- Home
- Kids
- Made in America
- Made in Europe
- Memorial
- Music
- Occupations
- Patriotic
- Pets and Animals
- Picture Frames
- Piggy Banks
- Religious
- Santa & Snowman
- Snow Globes
- Space & Technology
- Sports
- Table Decorations
- Teachers and School
- Transportation
- Vacation and Travel
- Valentine
- Western
Review this product!
Paris Cafe and Paris Bakery
Personalized Christmas Ornament or Personalized Christmas Table Top Decoration$28.95
Ooh la la! The most unique personalized Paris ornament you'll find anywhere! This glass ornament has a very detailed resin scene in the middle that if you turn one way it is a fine Paris bakery that you just know serves the finest baguettes and croissants. If you turn the glass globe to the other side, you will find an adorable French bistro scene with high table and chairs. You can almost believe you are in France with this personalized Paris ornament.
Material: Glass Ball with Resin Scene


text:
Thought-Provoking Academic Lectures at the Clark in February and March
For Immediate Release
February 02, 2009
National and international scholars, art critics, and museum professionals selected as Clark Fellows present thought-provoking and intriguing lectures at the Sterling and Francine Clark Art Institute during the academic year. These free scholarly lectures are open to the public and held on selected Tuesdays at 5:30 pm. Refreshments are served.
Fellows Lectures scheduled during February and March are:
Clark Fellow Claudine Cohen, Maître de Conférences at the École des Hautes Études en Sciences Sociales (School for Advanced Studies in the Social Sciences) in Paris, will present the lecture "Studies in Paleolithic Art (1859-2009)" on February 17. Cohen is the author of numerous studies on prehistory, on prehistoric art, and on the notion of prehistory and paleontology, including L'homme des Origines (Paris, 1999), La Femme des origines (Paris, 2003), Le Destin du Mammouth (Paris, 2004), and most recently, Un Néandertalien dans le metro (A Neanderthal in the Subway) (Paris, 2007). Her Clark project is a critical study of the history of knowledge on paleolithic art throughout western Europe (1859–2009) as a scientific endeavor and a hermeneutical enterprise.
On March 3, Clark-Oakley Fellow Aamir Mufti will present the lecture "Parting Lines: The Iconography of India's Partition." Mufti is associate professor of comparative literature at the University of California, Los Angeles. His academic training is in literature and anthropology, and his areas of specialization include colonial and postcolonial literatures, with a primary focus on India and Britain, and nineteenth- and twentieth-century Urdu literature in particular; Marxism and aesthetics; Frankfurt School critical theory; minority cultures; and the history of anthropology. He is the author of Enlightenment in the Colony: The Jewish Question and the Crisis of Postcolonial Culture (2007) and co-editor of Dangerous Liaisons: Gender, Nation, and Postcolonial Perspectives (1997). His Clark-Oakley project undertakes a new understanding of the artistic representation of India's partition in comparative and global terms. The focus will be on the work of Zarina, a New York-based printmaker.
Clark Fellow Charles Palermo, assistant professor of art history at the College of William and Mary, Williamsburg, Virginia, will present the lecture "Picasso's False Gods" on March 17. His work focuses on early- twentieth-century modernism, and he is the author of Fixed Ecstasy: Joan Miró in the 1920s (2008) and of numerous articles in October, Art Bulletin, MLN, and other journals. His Clark project analyzes divisions within bodies in Picasso's "Blue" and "Rose" period work and uses them to explore themes (ambiguity between sacred and profane attitudes, etc.) through the work of Paul Gauguin, Paul Verlaine, Charles Morice, Guillaume Apollinaire, and Picasso.
The Sterling and Francine Clark Art Institute has announced 17 Clark Fellows for the 2008-2009 academic year. Clark fellowships are awarded to national and international scholars, critics, and museum professionals whose work extends and enhances the understanding of the visual arts and their role in culture. The program encourages a critical commitment to research in the theory, history, and interpretation of works from all periods and genres.
Since its inception in 2000, the Clark's Research and Academic Program has earned an international reputation as a foremost center for advancing the study of visual arts and for educating the next generation of art historians, professors, and museum directors and curators. The program engages the world's most creative and innovative visual arts scholars, from Clark Fellows who travel to Williamstown from throughout the world to pursue their research while in residence at the Clark, to prominent participants in pioneering international research collaborations, this year underway with institutions based in Paris and Johannesburg.
The Clark is one of the country's foremost art museums, as well as a dynamic center for research and higher education in art history and criticism with an international fellowship program; regular conferences, symposia, and colloquia; and an important art research library. The Clark, together with Williams College, jointly sponsors one of the nation's leading M.A. programs in art history, which has been part of the professional development of a significant number of art museum directors, curators, and scholars.
The Clark is located at 225 South Street in Williamstown, MA. The galleries are open Tuesday through Sunday, 10 am to 5 pm (open daily in July and August). Admission is free November through May. Admission June 1 through October 31 is $12.50 for adults, free for children 18 and under, members, and students with valid ID. For more information, call 413-458-2303 or visit www.clarkart.edu.


text:
post #121 of 319
10/9/06 at 10:39am
Delight, I saw on your blog, you cloth diaper. I didn't see where you kept them. Would you be willing to show a pic of your cloth in a small place. I'm having that dilemma now.
they had a display which was of a very tiny apartment (can't remember the square footage, it was smaller than Delight's) and they showed it all set up for two adults and a baby and it was SO great for ideas, I was very inspired!
All those things are within walking distance??? I'm so envious!! Wow, you live in a utopia!
I just wanted to add, the more stuff I purge, the richer I feel. I realize how much we really have. Funny, huh?
You just reminded me--I have FOUR cast iron skillets of roughly the same size. Hmmm...
Delight, I saw on your blog, you cloth diaper. I didn't see where you kept them. Would you be willing to show a pic of your cloth in a small place. I'm having that dilemma now.
ETA: I forgot to say that I too have been so inspired by you Delight. I went through my wardrobe and pared it down more. And did the kitchen too so we only have four sets of dishes out. I got rid of some toys too, but have quite a ways to go with those. I told my dh about your blog and pics and stuff and he got really inspired and wants to move to a small apartment in an area we love and really work on our debt. Thank you so much for the inspiration!
Delight- You are definitely an inspiration! Your place is so simple, neat, beautiful, and organized!
We currently are a family of 5 (with number 6 due in 11 days ) in a 430 sq ft apartment.
It has forced us to deal with issues that are so easily left undone when you can retreat into a different room in the house. Our family has become so much stronger and closer. It has also shown us how much we can live without. Filling your time up with family activities instead of shopping for stuff has improved all of our sanities
It's like if you have a larger family then you can't have a small space? I have 4 children and DH and I live in 1100sq ft now which is double (plus 144sq ft) the OP's space but in a freestanding
I am actually crying after looking at your pictures. Earlier tonight I took some pictures of my own house to show a friend, so I am emotional about the house at the moment to begin with. I am struggling to try and gain some control. We live in 2400 sq. feet that is about 85% filled and a cluttered mess. I have managed to keep the playroom and the kids rooms clean so that they have some peaceful places to play but the rest of the house is beyond me now. Thank you for sharing your pictures and decluttered life, it gives me some hope and encouragement.


text:
The Roundup: The week's TV picks, podcast connections, and more
Here's the news, "Nurse Jackie" isn't funny, it has funny moments, but it's a drama, take note TV Academy. [Photo courtesy Showtime]
If you have been watching Showtime's "Nurse Jackie" this season you will know that the show has gone to a very dark place and any humor that occurs is meant to highlight the drama. That's because "Nurse Jackie" is, and has always been, a 1/2 hour drama despite the TV Academy's insistence on nominating and awarding Edie Falco with Emmys for "Best Actress in a Comedy," something that should not happen this year if the Academy wishes to preserve what little credibiity it may have left. Delving deep into a battle with addiction and the collapse of her family, moments of levity are few and far between. On the flip side, Louis C.K. won resoundingly this weekend at the 2nd annual Comedy Awards in New York City (look for our report on the event here tomorrow) and we had better see similar honors bestowed upon FX's "Louie" this Fall, an innovative comedy show that delves into drama.
An interview with comedian Jo Koy, Comedy Central premieres "Jo Koy: Lights Out" on Sunday
Comedy Central
Comedy Central premieres "Jo Koy: Lights Out" on Sunday, April 1, at 10pm. [Photo courtesy of Comedy Central]
Comedian Jo Koy, a regular round table panelist who has been on E!'s "Chelsea Lately" literally several dozen times, has a new hour-long special premiering this Sunday night. We had the chance to talk to the busy comedian, who has a full schedule of theatre gigs on his plate, in addition to promoting his special, about what aspects of his life made it into his new act and what's been important to him as he came up. Find out more about Jo Koy and his schedule of shows at his website. Jo Koy next makes it back to the LA area in June for a string of shows at the Brea Improv. Preview a clip of "Lights Out" here.
This Sunday Comedy Central premieres "Jo Koy: Lights Out," you've worked with them before on other occassions, other specials, right?
Jo Koy: It's my second one! My second hour special. My first one was "Don't Make 'Em Angry" and this one I'm most excited about. This one was shot in my hometown, Los Angeles, and in this time I talk a lot more about my son, and a lot more stories about my Mom, the two things I really like to talk about. I really enjoyed it. I also got to introduce my grandmother into the act, another character involved in my special.


text:
Bath + Body
Dare to Discover
The creamy lather enriched with moisture-rich bee pollen, soothing aloe vera and hydrating honey caresses hands with gentle cleansing. Leaves hands softly scented. View All Ingredients.
When perfume is a work of art.
Smooth jasmine. Sheer roses. Heady hyacinth. Creamy lily of the valley. Lavish oak moss.
View the Goldleaf Collection.
Gold leaf hand wash
I love,love,love this fragrance! Every time I wear it people ask what I'm wearing. It's subtle and perfect for me because I don't like a heavy, perfume scent! I actually bought it the first time at a little shop in Medina, Ohio. Don't remember the name of it, and was hooked immediately !
Was this review helpful?
Yes No
Love It!
I love anything in the Goldleaf collection, the hand wash is divine, and the bath salts are wonderful and are an added addition to drawers and closets to give a lovely fragrance.
Interesting smell, nice fragrance for washing hands.
Goldleaf Hand Wash=Amazing!
I love the goldleaf collection! I decided to purchase the hand wash last Christmas for my mother-in-law, who is a nurse, and she absolutely loved it! I am now buying the goldleaf hand wash every other month to stay stocked up in the bathrooms and kitchen. The scent is just right for hand wash and lasts so long! I hope this helps!
Love it!!!
The fragrance lasts from hand washing to hand washing...and people ask what lotion I'm wearing..............the lotion is also great if you havn't tried it you should...
Water, Sodium Coco-Sulfate¹, Decyl Glucoside², Acrylates Copolymer, Cocamidopropyl Betaine¹, Glycol Stearate², Fragrance, Honey, Aloe Vera, Elder Flower Extract, Pollen Extract, Vitamin E², Glycerin², Coco-Glucoside², Glyceryl Oleate², Citric Acid², Sodium Hydroxide, Citronellol, Eugenol, Alpha-Isomethyl Ionone, Hexyl Cinnamal, Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde, Hydroxycitronellal, Linalool, Trisodium Ethylenediamine Disuccinate, Sodium Benzoate, Potassium Sorbate, Sodium Chloride, Caramel, Yellow 5 (CI 19140), Red 33 (CI 17200), Yellow 10 (CI 47005)
¹Coconut and/or Palm, ²Mixed Plant
Featured Ingredients:
Aloe Vera